ABSTRACT

In this review, the role of positron emission tomography (PET) in prostate cancer will be discussed. Fluorodeoxyglucose (FDG) PET is the most important in determining early staging of disease in patients with aggressive prostatic tumors and for monitoring response to therapy in more advanced patients. Choline PET provide better accuracy than FDG in the detection of local disease, nodal involvement, and distant metastases in prostate cancer but insufficient in low PSA levels. A novel tracer prostate specific membrane antigen (PSMA) can detect prostate cancer relapses and metastases in also low PSA levels.